The objective of this study was to develop pH independent controlled release matrix tablets of Ondansetron HCl by using Multi component Complexation technique, Methocel K100M as release retarding materials and HP β-cyclodextrin was selected as release modulators. Ondansetron is weakly basic drug and their salts shows pH-dependent solubility that may show drug release problems at higher pH of small intestine. Incorporation of weakly basic drugs, exhibiting pH dependent solubility, into oral controlled release delivery systems shows pH dependent release profiles. In the present investigation, an attempt was made to pH-solubility dependence of drug and dissolution enhancement was attained by inclusion complex of Ondansetron with HP-β-cyclodextrin at 1:1 (drug: β-CD) molar ratio and then prepared complex hydroxyl propyl methyl cellulose controlled released matrix tablets. The in vitro drug release studies were carried out in pH1.2 buffer for 2 hrs and then in pH 6.8 phosphate buffer up to 24 hrs. The formulated matrix tablet F4 (without complexation) was very slow and drug is not released completely from matrix tablets in 6.8 pH phosphate buffer. The matrix tablets prepared using HP β-cyclodextrin with PVP (F8) showed a superior dissolution rate and good dissolution profile that was comparable to without complexation of Ondansetron HCl. Dissolution results showed pH independent controlled and almost complete release behavior of Ondansetron HCl up to 24 hrs time period. The drug release mechanism of the HPMC matrix tablets was found to be quasi Fickian mechanism. These results suggested that the oral bioavailability of Ondansetron HCl was significantly improved by Multi component Complexation strategies.
INTRODUCTION
In the antiemetic category, across a broad range of therapeutic indications,. Ondansetron hydrochloride is a serotonin sub type-3 (5-hydroxytryptamine-3) receptor antagonist. It is a widely used drug for the treatment of several therapeutic purposes like antiemetic especially it is used in the prevention of post operative nausea and vomiting and chemotherapy or radiation induced nausea and vomiting. The pharmacokinetic outline of Ondansetron which has a half-life of about 3-6 hrs with a time to peak plasma approximately 2 hrs. The present marketed available oral dosage form of Ondansetron liquid dosage form and orally dissolving tablet are indicated for administration in multiple daily doses, potentially over a multiple days. There is still a need for sustained safeguard predominantly when patients are faced with extended or recurrent treatment during which they are at risk of CINV and PONV. 1, 2 The recommended oral dose regimen of Ondansetron hydrochloride is 8 mg, three times a day. The dose of Ondansetron HCl should be varying to 8-32 mg a day. The selection of dose regimen should be determined by the severity of the treatment. Ondansetron solubility exhibits high solubility in stomach at low pH (pH 1.2) and at higher pH (6.8 pH phosphate buffer), it exhibits poor solubility. Ondansetron HCl is weakly basic pH dependent soluble drug. The drug precipitation was found upon entry into the small intestine that may also affect the amount of drug obtainable for uptake throughout the intestinal mucosa. 3, 4 The availability of existing literature indicates that some of the techniques were developed in previous works, we have reported for pH-independent drug release. Out of that, one is gastro retentive drug delivery system in which the drug will float constantly for long period of time which is a question mark and also in-vitro/ in-vivo correlation is very poor. And another technique was developed pH modulating agents; this technique was somewhat better but the formulator was observed some manufacturing defects and prolonged drug release is very difficult. Then, in an effort to reach, the present investigation is aimed to develop a pH-independent control drug release dosage form of Ondansetron HCl for better pH independent dissolution properties as well as controlled release rate of Ondansetron. Hence, OND-HP-CD complexes have prepared and an optimal formulation was consequently designed by the combination of these complexes into HPMC-based hydrophilic Matrix tablet once daily dosage form. [5] [6] [7] One potential method of optimizing the efficacy of drug activity is through the use of rationally designed carrier materials such as Hydroxypropyl beta cyclodextrin (HPßCD) encapsulation technology. A chemically modified HP--CD, became a more interesting option than ß-CD to achieve Complexation because of better physicochemical properties and enhanced inclusion behavior. Studies had proven that this CD derivative is able to increase drug oral bioavailability With HP-ßCD, an aqueous drug complex preparation is very simple, of all the CD derivatives accessible, HP-ßCD is the safest, as it does not permeate the membranes, enhance the dissolution, of poorly water-soluble pH dependent soluble drugs. A recent publication from Gould and Scott concludes that HP-ßCD is well tolerate in most species, particularly if dosed orally, and shows limited toxicity. [8] [9] [10] Hence' the present study was undertaken to evaluate, by means of Multi component complexes in association with high molecular weight Methocelk100M matrix tablets as strategies to improve Ondansetron HCl oral bioavailability and also to obtain a delayed therapeutic effect of the drug as compared with a conventional formulation. The use of HP-cyclodextrin (CD) Multi component complexation has been attempted to overcome such pH dependent solubility and dissolution drawbacks.
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MATERIALS AND METHODS
Ondansetron was received as a gift sample from Pranami Drugs Pvt. Ltd., Gujarath . HP-bete-cyclodextrin and Methjocel k100M was purchased from Yarrow chem. Product Mumbai, Micro crystalline cellulose (Avicel PH 101), Sodium hydroxide, Magnesium Stearate, and Talc were purchased from ( S.D. Fine Chem Ltd., India), respectively.
Analytical Method
Calibration curve of Ondansetron HCl was determined in 0.1 N HCl and 6.8 phosphate buffer at 249 nm using a UV-Visible spectrophotometer (Elico SL 210 UV-VIS Spectrometry Analytical Instruments Pvt Ltd, India). This calibration curve was used for estimation of drug release and drug content determination.
Solubility of Ondansetron HCl
The solubility of Ondansetron HCl was determined by using simulated gastric fluid without enzymes (SGF pH 1.2), pH 6.8 phosphate buffer and in pH 7.4 phosphate buffer. The solubility of the API was determined by the equilibrium solubility method. Which employs up to the saturation of a solution to obtain by stirring an excessive of API need to add in the medium until equilibrium is achieved. After equilibrating the solution was kept in shaker water bath (37 ± 1 0 C) up to 24 h for maximum solubility of the drug. After that the samples were removed from shaker bath and filtered with 0.22 µm nylon non-pyrogenic disposable syringe filter. Finally the filtered solution was diluted and estimated by using UV-Visible Spectrophotometer (ELICO SL-210).
Excipient Compatibility Studies
In order to evaluate the reliability and compatibility of the drug with polymers in polymer-drug matrix, FTIR spectra of drug-polymer (1:1) powder mixture were recorded by the Potassium Bromide pellet method at the resolution rate of 4cm -1 . The FTIR-Spectrum was integrated in transmittance mode at the wave number range 400-4000 cm. (Jasco FTIR 6100 type-A, Japan) and the comparative spectra were demonstrated.
PREPARATION OF ONDANSETRON HCL-MULTICOMPONENT COMPLEXES
Physical mixture
Perfectly weighed quantities of drug and polymer carrier were weighed taken in a china dish were mixed systematically The resultant mixture was passed through sieve number 100 # and was stored in desiccators for the complete removal of moisture and was tested for the content uniformity. Drug: polymer molar ratios of 1:1 were prepared.
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Kneading Method
In this method the drug and carriers are used in different molar ratios (1:1). Both drug and carrier was triturated by using a small volume of Ethanol and water (1:1) to form a thick paste, which was kneaded up to 60 minutes and then kept for air dry. Then the dried mass was dented and crushed and sifted through 100# and stored in desiccators for further studies.
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Solvent evaporation method
The necessary quantities of drug and cyclodextrin were dissolved in sufficient quantity of water-ethanol solvent mixture (1:1,) and evaporated on a water bath at 50°C with stirring. Each solid product was sieved through #80 and stored in desiccators.
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Calculation of Once Daily Dose for Ondansetron HCl
The total dose of ondansetron HCl for once-daily controlled release formulation was calculated by using available pharmacokinetic data using fallowing equation
Dt = Dose [ 1+ (0.693*t)/t ½)]
Where, Dt indicates total dose of drug for controlled release, Dose is the immediate release part (4 mg), t indicates time during which controlled release is desired i.e. 24 h, and t1/2 = half life of the drug (3 h to 5 h).
Preparation of HPMC Matrix Tablets
Tablets containing 25 mg of Ondansetron hydrochloride were prepared by direct compression method. The various formulations used in the preliminary study and Complexation technique are shown in the ( Table 1, 2) The respective powders Ondansetron HCl-HP-betacyclodetrin complexes equaling to 25 mg of Ondansetron, HPMC K100 M CR, Avicel pH101,and were passed through sieve blended thoroughly with a mortar and a pestle. Magnesium stearate and talc were added to the blend and blended for further 5 min. Tablets were prepared using 8 mm die punch with Rotary tablet -punch tablet press (CADMACH, PRESS, INDIA. All tablet formulations contained 25 mg of Ondansetron or its equivalent. The Hardness for all the formulations was adjusted to 5-6 kg/cm 2 (Monsanto hardness testerMacro Scientific Works, Delhi, India).
Estimation of ondansetron:
An ultraviolet (UV) Spectrophotometric method, based on the measurement of absorbance, at 249 nm, was developed and used for the estimation of Ondansetron HCl pure drug and formulation with excipients. The method Followed Beer's law in the concentration range of 2 to10 μg/ml, with good correlation coefficient (0.9991). When a standard drug solution was assayed repeatedly (n = 5), the relative error (accuracy) and relative standard deviation (precision) were found to be 0.69 and 1.2%, respectively. No interference from the excipients used was observed.
Tablets containing complex of drug: β-CD
Complex prepared by different method were subjected for evaluation of drug content in the Drug:cycodextrin (1:1) complex and the data obtained is shown in table 3. It was observed that the practical yield was 71 to 95%. The maximum drug content was found to be 90.26% in the solvent evaporation method. 16 
Estimation of drug content in the matrix tablets
Five tablets were accurately weighed and powdered. Tablet powder equivalent to 25 mg of Ondansetron HCl was taken into a 100 ml volumetric flask. Initially 50 ml of ethanol was added into the volumetric flask and allowed to stand for 6 hrs with Sonication for the complete solubility of drug. Make up volume up to 100 ml with methanol, centrifuge the mixture and 1ml the supernatant liquid was filtered, the solution was subsequently diluted with purified water and analyzed for Ondansetron content by measuring absorbance at 249 nm.
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In vitro release studies
The in vitro dissolution studies were passed out using US Pharmacopeia (USP) apparatus type 2 (VEEGO, Instruments Corporation, Mumbai, India) at 50 rpm. The dissolution medium consisted of 0.1 N hydrochloric acid pH 1.2 for the first 2 hr and the phosphate buffer pH 6.8 from 3 to 24 hr (900 ml), maintained at 37°C ± 0.5°C. The drug release at different time intervals was measured by a (ELICO SL-210 UV-visible spectrophotometer) at 249 nm. The release studies were conducted in triplicate, and the mean values of the percentage of drug released were plotted versus time.
Characterization of granules
Before to compression, the prepared granules were evaluated for their characteristic parameters, such as bulk density, tapped density, Carr's index, angle of repose, Hauser's ratio. Carr's compress ability index was determined from the bulk and tapped densities using a digital tapped density apparatus (Electro lab Ltd, India).
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RESULTS AND DISCUSSION
pH-dependent solubility of weakly basic drug:
The solubility of Ondansetron was high under acidic pH conditions but decreased sharply when pH increased. Indeed, the estimated solubility values for each pH solution studied were 23.3 mg/ml at pH 1.2, and 0.037mg/ml at pH 6.8, the drug was immediately precipitated and it formed large crystals. SEM analysis was shown in (Figure 1 ) The solubility studies reported clearly illustrate the impact of pH on Ondansetron HCl solubility and dissolution. From the solubility values obtained, it is predictable that the extent of OND dissolution in the gastric environment will be high. Oppositely, under the pH values generally found in the upper regions of the gastrointestinal tract, the solubility and dissolution of pure OND will not be sufficient for complete dissolution of the doses .The solubility studies was revealed OND HCl is a absolutely pH dependent soluble drug. Hence in this investigation an attempt was made to develop a suitable pH independent controlled released matrix tablets. Drug solubility was shown in is shown Table 4 .
Scanning electron microscopy
The SEM micrographs performed on the Ondansetron API powder and precipitated powder in phosphate buffer pH 6.8.The pure Ondansetron particle size is small diameter than precipitated powder .the images was conformed that the drug particle size was increased in precipitated form of the powder than pure Ondansetron HCl powder form. SEM micrographs were shown in Figure 1 .
FTIR Studies
The FT-IR of ondansetron HCl and polymer mixtures and optimized matrix tablets dosage form studied by KBR pellet technique. The Ondansetron HCl exhibited characteristic peaks at 3,394 and 1,633 cm, attributed to O-H stretching and C=O stretching vibrations. The physical spectrum showed significant shift in peaks of Ondansetron HCl change the intensity peaks were found. The formulation of Methocel K100M with-HP-beta-cyclodetrin formulation was studied the band at 3,499 cm for O-H stretching and 1,699 cm for C=O Stretching was found. Pure OND displays a peak characteristic of the N-H bending vibration at 1633 cm-1 and a band with main strong peak at 1280.62 cm-1 and 760.1 cm-1 indicative of C-N stretching and ortho-substitution phenyl C-H bending respectively. It is evident that peaks of different functional groups of OND in various solid dispersions were some deviated from peaks of pure drug. Therefore it indicates that formation of inclusion complex OND with CDS (Figure 2, 3) . The following characteristic peaks were observed in IR spectra ( 
DSC STUDIES
Differential scanning calorimetric Thermo grams performed in Figure 4 (a) is pure drug and (b) is precipitated powder in 6.8 phosphate powder respectively, reveals that the melting point of OND HCl is 206.110C and that of OND HCl in the precipitated powder is 236.170C. While there is a few differences in the melting points, it indicates that the drug stabilility will be modifying in precipitate form it will effect in drug release in 6.8 pH.
Thermo grams has shown in Figure 4 .
XRD STUDIES
X-ray diffraction studies were then performed, in order to obtain more information to support DSC and TG results. The studied drug has a crystalline structure. peaks of Ondansetron pure API and precipitated powder peaks are altered within the precipitated powder of Ondansetron HCl in 6.8pH medium. Spectrums are shown in Figure 5 .
Evaluation of flow properties of powder blend
Prior to compression, all the formulations were evaluated for their flow property .The powder blends of the formulations were evaluate for the flow properties. The results were showed in better flow properties with specified values. These results indicated that the powder blends of all formulations were suitable to compress tablets by direct compression method. However, flow properties of formulation powder have Avicel PH 101 were superior when compared to Lactose. The results obtained point to that the powder flow properties were within the pharmacopoeias limits. (Table 5 ).
Evaluation of post-compression parameters of Ondansetron HCl matrix tablets
The compressed Ondansetron HCl matrix tablets were evaluated for properties like weight variation, friability and hardness drug content, of prepared matrix tablets was within 98 ± 3% of labeled claim. A good degree of uniformity in weight of tablets was achieved for all batches of tablet formulations prepared. The percentage deviation was within ± 4, which indicates excellent uniformity in weight of all formulations of tablet formulations. The friability values of all batches of tablet formulations prepared were less than 1% variation. The hardness of all batches of tablet formulations compressed ranged between 5.5 To 6kg/cm 2. Preliminary studies were conducted for selecting the diluents to be used and Avicel PH 101 was selected as the diluents, as it gave good cohesiveness when compressed with controlled release polymers. The investigated tablet results summarized in the following tables (Table 6 ).
Polymer Optimization of Controlled Released Tablets
The matrix forming tablets were studied in different pH mediums, from the results, F1-F3 formulations was not capable to control the drug release in 0.1N HCl. A remarkable difference in the drug release was observed in pH 1.2 SGF and pH 6.8 phosphate buffers. The drug release from the matrix tablet in pH 1.2 was relatively faster from all the formulations. The result was found low concentration of Methocel K100M polymer burst release was observed in SGF pH 1.2, consequently precipitation was observed in pH 6.8 phosphate buffer. F4 formulation (containing Methocel K100M 1:4 ratio), showed that with optimized concentration of approximately 26.24% in pH 1.2 after 2h and 65% of drug release in 6.8 phosphate buffer after 24h respectively, It was found pH dependent and incompletely drug release was found from matrix tablet.. The matrix tablets of Ondansetron HCl were prepared optimized constant polymer concentration of HPMC mentioned in the preliminary trails (1:4), (table 1) . . The release profiles of Ondansetron HCl from hydrophilic HPMC-based matrix formulations (F1-F4) are presented in Figure  6 . Based on preliminary trail studies, The basic nature of ondansetron HCl, the release of the drug from All formulations was<40% in the first 2 hour of the dissolution testing (pH 1.2) the drug release predictable on Ondansetron HCl dissolution at pH6.8 is very less. the drug release need to controlled in pH 1.2 because Ondansetron solubility was found it is highly soluble in pH 1.2, where as another object drug release need to enhance in pH 6.8 phosphate due to pH dependent solubility. [19] [20] [21] Therefore, Multi component complexation was attempted to improve the dissolution performance of the drug over a pH range .Hence, hydrophilic HPMC-based matrix formulations, containing the drug in the form of HP β-cyclodextrin -multi component complexes, were designed to overcome the Ondansetron solubility drawback at higher pH values and to extend drug release for a longer period of time without the risk of precipitation. However, drug release was nearly complete in the end of the dissolution experiment, almost indeed because of higher solubility and dissolution rate of multicomponent complexation matrix tablts. Therefore, there is a clear difference in the in vitro drug release characteristics of with HP β-cyclodextrin based matrix tablets as compared with. hydrophilic HPMC based matrix Ondansetron HCl formulations . Preliminary studies were conducted for selecting the diluent to be used and Avicel PH 102 was selected as the diluent as it gave good cohesiveness when compressed with controlled release polymers.
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Effect of Multi Component Technique on Ondansetron HCl
The Solid Multi-component complexes, OND-β CD and OND-HP β-CD-, with and without PVP, were prepared by solid dispersion method as described in briefly, equimolar amounts of CDs and OND were dissolved in water and Ethanol solution, respectively. The preliminary drug release study of optimized controlled released polymer concentration formulation F4(madeup of 30% MethocelK100),The drug release 25% was released in first 2h in 0.1N HCl further drug release gradually decreased in pH 6.8 phosphate buffer only 65% of drug was released up to 24h. In case of formulation F5-F7 (containing OND-β CD) the drug release was 85% in 24 hours the drug release was enhanced through complex with -β CD. Moreover the above formulation with OND-β CD were not satisfied the limited drug release was found in 6.8 pH phosphate buffer. But complete drug release was not found in formulation .the formulation with OND-HP β-CD (F8) drug release was 94% of drug release extended up to 24 hours, Hence the complete drug release from dosage form up to the maximum time period (24 h) was found in pH 6.8 phosphate buffer with HP β-CD. The grade and concentration of the controlled release polymer and the effect of cyclodextrin. As once daily dosage form Ondansetron tablets are not available in the Indian market, theoretical pH independent released oral dosage form is needed for Ondansetron HCl, for once-a-day (24 hours) administration, was calculated, based on its pharmacokinetics as suggested by Wagner. The selection criteria of drug release study was on the basis of <20% drug release during first two hour in 0.1N HCl of the study to control dose dumping., in case 6.8 phosphate buffer >90% drug release up to 24 h. Among all the formulations, F8, HP-β-Cyclodextrin with PVP gave greater release, when compared to β-Cyclodextrin, this Multi component complexation technique was found suitable for pH independent controlled drug release of Ondansetron HCl over 24 hrs. 19-20. The optimized formulation comparative released profile was shown in (Figure 7 and Table 7 )
Mechanism of drug release from matrix tablet
To identify the mechanism of drug release from these formulations, the data were treated according to firstorder (log cumulative percentage of drug remaining versus time), Higuchi's 21 (cumulative percentage of drug released versus square root of time), and Korsmeyer's 22 (log cumulative percentage of drug released versus log time) equations, along with zero order (cumulative amount of drug released versus time) pattern. The release rate kinetic data (correlation coefficients) can be seen in Table 8 . When the data were plotted according to the zero-order equation, the formulations showed linearity with correlation coefficient values between 0.9538 and 0.9809. When the data were plotted according to the first order equation, the formulations show a just linearity, with significantly higher correlation coefficient values than the zero order plots, (0.962-0.9731) (t = 5.8 P < 0.001). First-order release rate constants for the tablets prepared with β CD The same observation was found with HP β CD also., matrix tablets prepared with HP β CD showed significant release (F = 22764, P < 0.05). The effect of β CD/HP β CD on the drug release from the matrix tablets was attributed to the solubility enhancement effect of pH of the dissolution medium.
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Stability Studies
After three month time interval, outcome of accelerated stability studies of optimized formulation indicate it is stable at 40 0 C / 75%. When the optimized batch Ondansetron HCl (F8) was subjected for organoleptic properties, appearance, friability, remains unaffected. The drug content and drug release were found to be (6.32 ± 0.05 kg/cm2, 92.72 ± 0.68 and 97.32 ± 1.4%, ) respectively.
CONCLUSION
The present study was demonstrated to Enhance dissolution of pH dependent soluble Ondansetron HCl using two different types of formulations (solid dispersions and Matrix tablets) by using Multicomponent complexation was attempt to progress the dissolution performance of the drug over a pH range. From the result, it was clear and evident that even the solid dispersion (SD) technique with HP-β-cyclodextrin and matrix tablets technique had improved the dissolution rate of drug to a huge extent. The percentage of the dissolution rate was higher in solid dispersion HP-β-cyclodextrin formulation than β-cyclodextrin formulation. Finally, it could be concluded that with future the Multicomponent complexation technique tremendous potential in the area of controlled release dosage form continue to enable novel applications in drug delivery and solve problems linked with the delivery of poorly pH dependent soluble drugs. 
SUMMARY GRAPHICAL ABSTRACT
• The pH independent controlled drug delivery system tablet concept for weakly basic pH dependent soluble drugs has been designed to release the drug at any pH of the Medium.
• The higher viscosity polymer (HPMCK100M) had been seen to inhibit the initial burst release of Ondansetron HCl, due to the drug nature the solubility is 23mg/ml in pH 1.2 and 0.339mg/ml in 6.8 pH phosphate buffer medium.
• It is a challenging to prepare a pH dependent soluble drug for pH independent drug release in a single unit dosage form we achieved in a simple technique.
• The hydroxypropyl-β-cyclodextrin (HBC) polymer in HPMC matrix tablet had been seen to enhance the drug release in 6.8 pH phosphate buffer and controlled drug precipitation when compared to β-cyclodextrin. 
